Page 1961 - Hematology_ Basic Principles and Practice ( PDFDrive )

1737.e4 Part VII Hematologic Malignancies

nucleotide sequencing leads to imprecise allele identification. J Transl 165. Opelz G, Vanrenterghem Y, Kirste G, et al: Prospective evaluation of
Med 2(1):30, 2004. pretransplant blood transfusions in cadaver kidney recipients. Trans-
143. Wang EAS Discrimination of genetic polymorphism using DNA chips. plantation 63(7):964–967, 1997.
2001;Sect. 45. 166. Terasaki PI: The beneficial transfusion effect on kidney graft survival
144. Wang E, Adams S, Zhao Y, et al: A strategy for detection of known attributed to clonal deletion. Transplantation 37(2):119–125, 1984.
and unknown SNP using a minimum number of oligonucleotides 167. Rubinstein P: HLA matching for bone marrow transplantation–how
applicable in the clinical settings. J Transl Med 1(1):4, 2003. much is enough? N Engl J Med 345(25):1842–1844, 2001.
145. Tiercy JM, Bujan-Lose M, Chapuis B, et al: Bone marrow transplanta- 168. Petersdorf EW, Hansen JA, Martin PJ, et al: Major-histocompatibility-
tion with unrelated donors: what is the probability of identifying an complex class I alleles and antigens in hematopoietic-cell transplanta-
HLA-A/B/Cw/DRB1/B3/B5/DQB1-matched donor? Bone Marrow tion. N Engl J Med 345(25):1794–1800, 2001.
Transplant 26(4):437–441, 2000. 169. Champlin RE, Goldman JM, Gale RP: Bone marrow transplantation
146. Tiercy JM, Villard J, Roosnek E: Selection of unrelated bone marrow in chronic myelogenous leukemia. Semin Hematol 25(1):74–80, 1988.
donors by serology, molecular typing and cellular assays. Transpl 170. Clift RA, Buckner CD: Marrow transplantation for acute myeloid
Immunol 10(2–3):215–221, 2002. leukemia. Cancer Invest 16(1):53–61, 1998.
147. Duquesnoy RJ, White LT, Fierst JW, et al: Multiscreen serum analysis 171. Hansen JA, Gooley TA, Martin PJ, et al: Bone marrow transplants from
of highly sensitized renal dialysis patients for antibodies toward public unrelated donors for patients with chronic myeloid leukemia. N Engl J
and private class I HLA determinants. Implications for computer- Med 338(14):962–968, 1998.
predicted acceptable and unacceptable donor mismatches in kidney 172. Storb R, Leisenring W, Anasetti C, et al: Long-term follow-up of allo-
transplantation. Transplantation 50(3):427–437, 1990. geneic marrow transplants in patients with aplastic anemia conditioned
148. Duquesnoy RJ, Marrari M: Determination of HLA-A,B residue by cyclophosphamide combined with antithymocyte globulin. Blood
mismatch acceptability for kidneys transplanted into highly sensitized 89(10):3890–3891, 1997.
patients: a report of a collaborative study conducted during the 173. Lucarelli G, Clift RA, Galimberti M, et al: Marrow transplanta-
12th International Histocompatibility Workshop. Transplantation tion for patients with thalassemia: results in class 3 patients. Blood
63(12):1743–1751, 1997. 87(5):2082–2088, 1996.
149. Duquesnoy RJ: HLAMatchmaker: a molecularly based algorithm for 174. Anderson JE, Appelbaum FR, Schoch G, et al: Allogeneic marrow
histocompatibility determination. I. Description of the algorithm. Hum transplantation for myelodysplastic syndrome with advanced disease
Immunol 63(5):339–352, 2002. morphology: a phase II study of busulfan, cyclophosphamide, and
150. Claas FH, De Meester J, Witvliet MD, et al: Acceptable HLA mis- total-body irradiation and analysis of prognostic factors. J Clin Oncol
matches for highly immunized patients. Rev Immunogenet 1(3):351–358, 14(1):220–226, 1996.
1999. 175. Teshima T, Ferrara JL: Understanding the alloresponse: new approaches
151. Lobashevsky AL, Senkbeil RW, Shoaf JL, et al: The number of amino to graft-versus-host disease prevention. Semin Hematol 39(1):15–22,
acid residues mismatches correlates with flow cytometry crossmatching 2002.
results in high PRA renal patients. Hum Immunol 63(5):364–374, 176. Ratanatharathorn V, Ayash L, Lazarus HM, et al: Chronic graft-versus-
2002. host disease: clinical manifestation and therapy. Bone Marrow Transplant
152. Nambiar A, Duquesnoy RJ, Adams S, et al: HLAMatchmaker- 28(2):121–129, 2001.
driven analysis of responses to HLA-typed platelet transfusions in 177. Flowers ME, Kansu E, Sullivan KM: Pathophysiology and treatment
alloimmunized thrombocytopenic patients. Blood 107(4):1680–1687, of graft-versus-host disease. Hematol Oncol Clin North Am 13(5):1091–
2006. 1112, viii-ix, 1999.
153. Duquesnoy RJ: A structurally based approach to determine HLA com- 178. Barrett J, Childs R: The benefits of an alloresponse: graft-versus-tumor.
patibility at the humoral immune level. Hum Immunol 67(11):847–862, J Hematother Stem Cell Res 9(3):347–354, 2000.
2006. 179. Barrett J, Childs R: New directions in allogeneic stem cell transplanta-
154. Shoskes DA, Wood KJ: Indirect presentation of MHC antigens in tion. Semin Hematol 39(1):1–2, 2002.
transplantation. Immunol Today 15(1):32–38, 1994. 180. Childs R, Srinivasan R: Advances in allogeneic stem cell transplantation:
155. Semple JW, Freedman J: Recipient antigen-processing pathways of directing graft-versus-leukemia at solid tumors. Cancer J 8(1):2–11,
allogeneic platelet antigens: essential mediators of immunity. Transfu- 2002.
sion 42(7):958–961, 2002. 181. Feinstein L, Sandmaier B, Maloney D, et al: Nonmyeloablative hema-
156. Fuller TC, Fuller A: The humoral immune response against an HLA topoietic cell transplantation. Replacing high-dose cytotoxic therapy
class I allodeterminant correlates with the HLA-DR phenotype of the by the graft-versus-tumor effect. Ann N Y Acad Sci 938:328–337,
responder. Transplantation 68(2):173–182, 1999. discussion 337-339, 2001.
157. Liu Z, Colovai AI, Tugulea S, et al: Indirect recognition of donor 182. Mavroudis D, Barrett J: The graft-versus-leukemia effect. Curr Opin
HLA-DR peptides in organ allograft rejection. J Clin Invest Hematol 3(6):423–429, 1996.
98(5):1150–1157, 1996. 183. Michallet M: Graft-versus-host disease and graft-versus-leukemia.
158. Benichou G, Valujskikh A, Heeger PS: Contributions of direct and Hematol Cell Ther 38(5):459–460, 1996.
indirect T cell alloreactivity during allograft rejection in mice. J 184. Porter DL, Antin JH: The graft-versus-leukemia effects of allogeneic
Immunol 162(1):352–358, 1999. cell therapy. Ann Rev Med 50:369–386, 1999.
159. Rodey GE, Fuller TC: Public epitopes and the antigenic structure of 185. Shimoni A, Giralt S, Khouri I, et al: Allogeneic hematopoietic trans-
the HLA molecules. Crit Rev Immunol 7(3):229–267, 1987. plantation for acute and chronic myeloid leukemia: non-myeloablative
160. Salvatierra O, Jr, Melzer J, Potter D, et al: A seven-year experience preparative regimens and induction of the graft-versus-leukemia effect.
with donor-specific blood transfusions. Results and considerations for Curr Oncol Rep 2(2):132–139, 2000.
maximum efficacy. Transplantation 40(6):654–659, 1985. 186. Horowitz MM, Gale RP, Sondel PM, et al: Graft-versus-leukemia reac-
161. Clark BD, Geer LI, Park MS, et al: Association of high sensitiza- tions after bone marrow transplantation. Blood 75(3):555–562, 1990.
tion to the structure of HLA class I alleles. Clin Transpl 347–362, 187. Marmont AM, Horowitz MM, Gale RP, et al: T-cell depletion of HLA-
1991. identical transplants in leukemia. Blood 78(8):2120–2130, 1991.
162. Hardy S, Lee SH, Terasaki PI: Sensitization 2001. Clin Transpl 271–278, 188. Weiden PL, Flournoy N, Thomas ED, et al: Antileukemic effect of
2001. graft-versus-host disease in human recipients of allogeneic-marrow
163. Opelz G, Wujciak T, Dohler B, et al: HLA compatibility and organ grafts. N Engl J Med 300(19):1068–1073, 1979.
transplant survival. Collaborative Transplant Study. Rev Immunogenet 189. Sasazuki T, Juji T, Morishima Y, et al: Effect of matching of class I HLA
1(3):334–342, 1999. alleles on clinical outcome after transplantation of hematopoietic stem
164. Matzinger P: An innate sense of danger. Semin Immunol 10(5):399–415, cells from an unrelated donor. Japan Marrow Donor Program. N Engl
1998. J Med 339(17):1177–1185, 1998.